Five years ago, Arvinas collected $650 million in a single wire transfer from Pfizer, the largest upfront payment any biotech had received for a drug that had not yet reached Phase 3. The bet was on a new class of medicine called PROTACs, molecules engineered to grab a disease-causing protein and drag it to the cell’s own disposal machinery, destroying it rather than merely blocking it. Last May, that bet paid off in the most literal sense: the FDA approved VEPPANU, making it the first PROTAC therapy ever cleared for human use. The stock is down sharply over the past year.
That gap between scientific first and financial reality is the whole story here.
The quick read
Arvinas achieved a genuine scientific landmark in 2026, winning the first-ever FDA approval for its class of drug. But the deal structure means most of the commercial upside now belongs to partners, and quarterly revenue has collapsed to $500,000, a rounding error against a cash burn that consumed the better part of a year’s worth of reserves in nine months. The math says the company has enough cash to last into mid-2028, and a pipeline of early-stage programs behind the approved drug. The mood, at roughly 1.7 times annual sales, says the market is paying almost nothing for what comes next. The open question is whether any of those early programs can attract a new partner before the runway ends.
How the money moved
The Pfizer collaboration that funded Arvinas through its clinical years ended quietly in 2026. The research arm wound down on October 25, according to the Q3 2026 10-Q filed November 3. In its place sits a May 2026 licensing deal with Rigel Pharmaceuticals, which paid $70 million upfront, split evenly between Arvinas and Pfizer, to commercialize VEPPANU in the U.S. Rigel launched the drug that August. The royalties flowing back to Arvinas from that launch came to $500,000 for the entire third quarter, less than a rounding error against what Arvinas reported in the same quarter a year earlier, when Pfizer milestones were still arriving.
The Rigel deal also carries up to $320 million in contingent milestones and tiered royalties, again split evenly. That is real money, but it arrives only if VEPPANU sells well enough to trigger the thresholds, and Arvinas collects half of half. The company traded a large, certain partnership for a smaller, conditional one, and the income statement shows the difference immediately.
What the burn rate says
Arvinas used $127.9 million in operating cash over the nine months ended September 30, 2026, according to the Q3 filing. Think of it as spending roughly fourteen million dollars a month to keep the lights on and the trials running. Against a cash position of $558.9 million at quarter-end, that pace implies roughly thirty-nine months of runway at the current rate, though the company itself guides to the second half of 2028, a shorter window of roughly twenty to twenty-six months, reflecting anticipated increases in spending as the pipeline advances and the possibility that royalty income may not fully offset higher trial costs ahead.
R&D spending fell sharply in Q3, dropping nearly eighteen million dollars versus the same quarter in 2025, mostly because vepdegestrant program costs fell once the drug was approved and Rigel took over the commercial operation. That cost reduction is real, but it also signals that the pipeline behind VEPPANU is still early and not yet consuming large trial budgets. The central analytical question is whether the pipeline can attract new partnership dollars before the cash position forces a dilutive equity raise.
The pipeline behind the landmark
The VERITAC-2 Phase 3 trial for VEPPANU continues enrolling, building on data from May 2025 showing the drug cut disease-progression risk by 43% compared to the standard treatment in patients with a specific mutation called ESR1. That is a meaningful clinical result, and it underpins the approval. But the commercial economics now belong primarily to Rigel.
Further back in development, ARV-393 is in Phase 1 dose escalation for non-Hodgkin lymphoma, with initial data expected at the ASH Conference in December 2026, per the November 3 earnings release. ARV-102, a Parkinson’s disease program, showed encouraging biomarker results in Phase 1 but its U.S. trial remains on FDA clinical hold, with EU and UK initiation targeted for 2027. ARV-6723 entered its Phase 1/2 trial in solid tumors during Q3, with first data not expected until the second half of 2027. These are genuinely early programs, and the data cannot yet tell us which, if any, will attract the kind of partnership that once funded the company’s growth.
The price and the history
Our data show Arvinas trading at 1.7 times annual sales, against a decade median of 20.5 times, placing it at the 2nd percentile of its own history. That is not a rounding error in valuation terms. A stock at the 2nd percentile of its own price-to-sales range is priced as if the market has largely stopped paying for future potential. Zacks Research downgraded the stock to “hold” on November 11, 2026, while HC Wainwright, citing the Q3 results, cut its analyst valuation estimate while keeping a “buy” rating. The average published estimate across analysts sits well above the current share price. That gap is not a forecast; it is a measure of disagreement, and disagreement at this scale usually means the outcome hinges on a binary event, in this case, a clinical readout or a new partnership deal.
Arvinas built something genuinely new. The filing shows a company now living on the royalties of a drug it no longer controls commercially, burning cash at a pace that leaves roughly two years of runway, and running a handful of early trials that have not yet produced partnership-grade data. The history is remarkable. The current math is tight.
Reading the numbers
- $558.9 million cash (September 30, 2026): Total cash, equivalents, restricted cash, and marketable securities per the Q3 10-Q. This is what the company has left to spend. At the nine-month burn rate of $127.9 million, a household analogy: a family with $558,900 in savings spending $127,900 a year has about four years at that pace, but Arvinas’s spending is not uniform and royalties may offset some of it, which is why the company guides to the second half of 2028 rather than a later date.
- $0.5 million Q3 revenue vs. $41.9 million a year earlier: Both figures from the Q3 10-Q. The prior year included Pfizer collaboration payments; the current quarter is royalties only. A shop that once earned $42 a day now earns fifty cents: the product still exists, but the economics of who owns the sale have changed entirely.
- $46.9 million Q3 R&D expense: From the Q3 10-Q, down $17.8 million from Q3 2025. R&D expense is what the company spends on laboratory work, clinical trials, and the scientists running them. The drop reflects VEPPANU leaving Arvinas’s budget now that Rigel owns commercialization. What remains is the cost of the earlier-stage pipeline.
- 1.7x price-to-sales ratio (our data): Price-to-sales is the price tag the market puts on each dollar of annual revenue, the way a buyer might pay two years of a shop’s sales to acquire it. Arvinas’s decade median is 20.5 times. At 1.7 times, the market is paying almost nothing for future revenue growth, either because it doubts that growth will arrive, or because it has not yet priced in what the pipeline could produce.
For the standing yardsticks on Arvinas: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Arvinas.
Sources
- Arvinas 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
- Arvinas Q3 2026 earnings release, November 3, 2026
- StockTitan: Arvinas 10-Q summary
- StockTitan: Arvinas Q3 2026 results and pipeline update
- MarketBeat: Zacks Research downgrade, November 11, 2026
- AllSci: FDA approves VEPPANU, May 2026
- Arvinas: VERITAC-2 ESMO data
- StockTitan: Arvinas 8-K, Rigel licensing agreement









